Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2019 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial

WESTMINSTER, Colo., April 23, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
March 18, 2019 08:30 ET | Source: ARCA biopharma, Inc.

Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology

WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
March 06, 2019 08:00 ET | Source: ARCA biopharma, Inc.

Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine

WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 27, 2019 16:15 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
February 20, 2019 07:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug

FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
December 20, 2018 16:01 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
November 14, 2018 16:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update

WESTMINSTER, Colo., Nov. 14, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
November 12, 2018 08:30 ET | Source: ARCA biopharma, Inc.

GENETIC-AF Phase 2B Clinical Trial Atrial Fibrillation Burden (AFB) Results Presented at American Heart Association 2018 Scientific Sessions

AF detection by implanted Medtronic devicesSimilar trends for benefit in favor of Gencaro compared to active comparator for AF risk reduction observed by continuous monitoring with implanted devices...
November 05, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA Biopharma announces phase 2B GENETIC-AF atrial fibrillation burden (AFB) results selected for presentation at american heart association 2018 scientific sessions

Approximately 25% risk reduction for recurrence of AF seen in favor of Gencaro over active comparator as measured by AFB WESTMINSTER, Colo., Nov. 05, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc....
September 18, 2018 08:30 ET | Source: ARCA biopharma, Inc.

ARCA biopharma Submits Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial

Gencaro potentially the first genetically-targeted treatment for heart failure patients at risk for atrial fibrillationPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right